{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:50:14Z","timestamp":1763988614114,"version":"build-2065373602"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82027804"],"award-info":[{"award-number":["82027804"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanxi Province Higher Education \"Billion Project\" Science and Technology Guidance Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03255-2","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:56:45Z","timestamp":1760522205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular disease mortality risk among patients with metastatic melanoma before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based study"],"prefix":"10.1186","volume":"30","author":[{"given":"Xiaoqin","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanni","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiannan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"3255_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:660\u201370.","journal-title":"Nat Immunol"},{"key":"3255_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"3255_CR3","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.jid.2017.07.006","volume":"137","author":"M Gassenmaier","year":"2017","unstructured":"Gassenmaier M, Eigentler TK, Keim U, Goebeler M, Fiedler E, Schuler G, et al. Serial or parallel metastasis of cutaneous melanoma? A study of the german central malignant melanoma registry. J Invest Dermatol. 2017;137:2570\u20137.","journal-title":"J Invest Dermatol"},{"key":"3255_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.28627","volume":"3","author":"W Deng","year":"2020","unstructured":"Deng W, Wang Y, Liu X, Liu J, Wang L, Yang Z, et al. Assessment of trends in second primary cancers in patients with metastatic melanoma from 2005 to 2016. JAMA Netw Open. 2020;3:e2028627.","journal-title":"JAMA Netw Open"},{"key":"3255_CR5","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391:1696\u2013708.","journal-title":"N Engl J Med"},{"key":"3255_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40257-022-00681-4","volume":"23","author":"F Aroldi","year":"2022","unstructured":"Aroldi F, Middleton MR. Long-term outcomes of immune checkpoint inhibition in metastatic melanoma. Am J Clin Dermatol. 2022;23:331\u20138.","journal-title":"Am J Clin Dermatol"},{"key":"3255_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ejca.2021.08.013","volume":"157","author":"O Hamid","year":"2021","unstructured":"Hamid O, Robert C, Daud A, Carlino MS, Mitchell TC, Hersey P, et al. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. Eur J Cancer. 2021;157:391\u2013402.","journal-title":"Eur J Cancer"},{"key":"3255_CR8","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392.","journal-title":"Lancet Oncol"},{"key":"3255_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"3255_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","volume":"17","author":"C Robert","year":"2020","unstructured":"Robert C, Marabelle A, Herrscher H, Caramella C, Rouby P, Fizazi K, et al. Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. Nat Rev Clin Oncol. 2020;17:707\u201315.","journal-title":"Nat Rev Clin Oncol"},{"key":"3255_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jaccao.2024.07.017","volume":"6","author":"Z Raisi-Estabragh","year":"2024","unstructured":"Raisi-Estabragh Z, Murphy AC, Ramalingam S, Scherrer-Crosbie M, Lopez-Fernandez T, Reynolds KL, et al. Cardiovascular considerations before cancer therapy. JACC CardioOncol. 2024;6:631\u201354.","journal-title":"JACC CardioOncol"},{"key":"3255_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaccao.2024.06.005","volume":"6","author":"DP Leong","year":"2024","unstructured":"Leong DP, Waliany S, Abdel -Qadir H, Atkins KM, Neilan TG, Lang NN, et al. Cardiovascular considerations during cancer therapy. JACC CardioOncol. 2024;6:815\u201334.","journal-title":"JACC CardioOncol"},{"key":"3255_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2024.06.006","volume":"7","author":"A Blaes","year":"2025","unstructured":"Blaes A, Nohria A, Armenian S, Bergom C, Thavendiranathan P, Barac A, et al. Cardiovascular considerations after cancer therapy. JACC CardioOncol. 2025;7:1\u201319.","journal-title":"JACC CardioOncol"},{"key":"3255_CR14","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299\u2013311.","journal-title":"Circulation"},{"key":"3255_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007307","volume":"11","author":"ZD Drobni","year":"2023","unstructured":"Drobni ZD, Gongora C, Taron J, Suero-Abreu GA, Karady J, Gilman HK, et al. Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer. J Immunother Cancer. 2023;11:e007307.","journal-title":"J Immunother Cancer"},{"key":"3255_CR16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"J-E Salem","year":"2018","unstructured":"Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579\u201389.","journal-title":"Lancet Oncol"},{"key":"3255_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216633","volume":"586","author":"J Zhang","year":"2024","unstructured":"Zhang J, Joshua AM, Li Y, O\u2019Meara CH, Morris MJ, Khachigian LM. Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma. Cancer Lett. 2024;586:216633.","journal-title":"Cancer Lett"},{"key":"3255_CR18","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the european society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS): Developed by the task force on cardio-oncology of the european society of cardiology (ESC). Eur Heart J. 2022;43:4229\u2013361.","journal-title":"Eur Heart J"},{"key":"3255_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","volume":"5","author":"JM Unger","year":"2019","unstructured":"Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol. 2019;5:326\u201333.","journal-title":"JAMA Oncol"},{"key":"3255_CR20","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jama.282.8.790","volume":"282","author":"R Temple","year":"1999","unstructured":"Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999;282:790\u20135.","journal-title":"JAMA"},{"key":"3255_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148:473\u201386.","journal-title":"Circulation"},{"key":"3255_CR22","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889\u201397.","journal-title":"Eur Heart J"},{"key":"3255_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afad068","volume":"52","author":"T Guan","year":"2023","unstructured":"Guan T, Jiang Y, Luo Z, Liang Y, Feng M, Lu Z, et al. Long-term risks of cardiovascular death in a population-based cohort of 1,141,675 older patients with cancer. Age Ageing. 2023;52:afad068.","journal-title":"Age Ageing"},{"key":"3255_CR24","unstructured":"Surveillance, epidemiology, and end results program. SEER. https:\/\/seer.cancer.gov\/index.html. Accessed 8 Mar 2025."},{"key":"3255_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12889-025-21279-5","volume":"25","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zeng S, Wang Z, Zhu Q, Li J, Ren X, et al. Cardiovascular mortality risk among small bowel adenocarcinoma patients: a population-based study. BMC Public Health. 2025;25:97.","journal-title":"BMC Public Health"},{"key":"3255_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102254","volume":"81","author":"A Adhikari","year":"2022","unstructured":"Adhikari A, Cha E, Antala D, Sapkota S, Bhattarai U. Changes in the survival of adult patients with metastasized melanoma with the approval of immune checkpoint inhibitors: a retrospective study from the United States database. Cancer Epidemiol. 2022;81:102254.","journal-title":"Cancer Epidemiol"},{"key":"3255_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"3255_CR28","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.2014.60.3654","volume":"33","author":"C Fung","year":"2015","unstructured":"Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB. Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol. 2015;33:3105\u201315.","journal-title":"J Clin Oncol"},{"key":"3255_CR29","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36:4391\u2013400.","journal-title":"Stat Med"},{"key":"3255_CR30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamadermatol.2022.1609","volume":"158","author":"Z Ruan","year":"2022","unstructured":"Ruan Z, Lu T, Chen Y, Yuan M, Yu H, Liu R, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol. 2022;158:745\u201353.","journal-title":"JAMA Dermatol"},{"key":"3255_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509\u201328.","journal-title":"Nat Rev Drug Discov"},{"key":"3255_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.36823","volume":"4","author":"SR Jang","year":"2021","unstructured":"Jang SR, Nikita N, Banks J, Keith SW, Johnson JM, Wilson M, et al. Association between sex and immune checkpoint inhibitor outcomes for patients with melanoma. JAMA Netw Open. 2021;4:e2136823.","journal-title":"JAMA Netw Open"},{"key":"3255_CR33","doi-asserted-by":"crossref","unstructured":"Ye Y, Otahal P, Marwick TH, Wills KE, Neil AL, Venn AJ. Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: an Australian population-based study. Cancer. 2019;125(3):442-452.","DOI":"10.1002\/cncr.31806"},{"key":"3255_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jnci\/djp537","volume":"102","author":"F Fang","year":"2010","unstructured":"Fang F, Keating NL, Mucci LA, Adami H-O, Stampfer MJ, Valdimarsd\u00f3ttir U, et al. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst. 2010;102:307\u201314.","journal-title":"J Natl Cancer Inst"},{"key":"3255_CR35","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"3255_CR36","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085\u20137.","journal-title":"Circulation"},{"issue":"2","key":"3255_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaccao.2019.11.013","volume":"1","author":"KR Chitturi","year":"2019","unstructured":"Chitturi KR, Xu J, Araujo-Gutierrez R, Bhimaraj A, Guha A, Hussain I, et al. Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer. JACC CardioOncol. 2019;1(2):182\u201392.","journal-title":"JACC CardioOncol"},{"key":"3255_CR38","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","volume":"266","author":"LJ Steinherz","year":"1991","unstructured":"Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672\u20137.","journal-title":"JAMA"},{"key":"3255_CR39","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104\u201314.","journal-title":"Circulation"},{"key":"3255_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/CEJ.0000000000000690","volume":"31","author":"AA Elshanbary","year":"2022","unstructured":"Elshanbary AA, Zaazouee MS, Abdelmonem M, Mohammed YA, Abdel-Aziz W. Risk factors for cardiovascular mortality and melanoma-specific mortality among patients with melanoma: a SEER based study. Eur J Cancer Prev. 2022;31:293\u2013300.","journal-title":"Eur J Cancer Prev"},{"key":"3255_CR41","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.40242","volume":"104","author":"T Helkkula","year":"2024","unstructured":"Helkkula T, Christensen G, Mikiver R, Ingvar \u00c5, Isaksson K, Nielsen K. Acral melanoma incidence and survival trends in 1990\u20132020: a nationwide, population-based study. Acta Derm Venereol. 2024;104:adv40242.","journal-title":"Acta Derm Venereol"},{"key":"3255_CR42","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamadermatol.2020.0470","volume":"156","author":"CM Olsen","year":"2020","unstructured":"Olsen CM, Thompson JF, Pandeya N, Whiteman DC. Evaluation of sex-specific incidence of melanoma. JAMA Dermatol. 2020;156:553\u201360.","journal-title":"JAMA Dermatol"},{"key":"3255_CR43","doi-asserted-by":"crossref","unstructured":"Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, et al. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Science translational medicine. 2022;14(669):eabo1981.","DOI":"10.1126\/scitranslmed.abo1981"},{"key":"3255_CR44","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","volume":"5","author":"Y Zamami","year":"2019","unstructured":"Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, et al. Factors associated with immune checkpoint inhibitor-related myocarditis. JAMA Oncol. 2019;5:1635\u20137.","journal-title":"JAMA Oncol"},{"key":"3255_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/01.CIR.0000048892.83521.58","volume":"107","author":"EG Lakatta","year":"2003","unstructured":"Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a \u201cset up\u201d for vascular disease. Circulation. 2003;107:139\u201346.","journal-title":"Circulation"},{"key":"3255_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/00365521.2018.1553061","volume":"54","author":"H Gudmundsdottir","year":"2019","unstructured":"Gudmundsdottir H, M\u00f6ller PH, Jonasson JG, Bj\u00f6rnsson ES. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study. Scand J Gastroenterol. 2019;54:69\u201375.","journal-title":"Scand J Gastroenterol"},{"key":"3255_CR47","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jaad.2020.05.088","volume":"83","author":"S Rachidi","year":"2020","unstructured":"Rachidi S, Deng Z, Sullivan DY, Lipson EJ. Shorter survival and later stage at diagnosis among unmarried patients with cutaneous melanoma: a US national and tertiary care center study. J Am Acad Dermatol. 2020;83:1012\u201320.","journal-title":"J Am Acad Dermatol"},{"key":"3255_CR48","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s11764-017-0627-y","volume":"11","author":"RM Merrill","year":"2017","unstructured":"Merrill RM, Johnson E. Benefits of marriage on relative and conditional relative cancer survival differ between males and females in the USA. J Cancer Surviv. 2017;11:578\u201389.","journal-title":"J Cancer Surviv"},{"key":"3255_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.tcm.2019.05.012","volume":"30","author":"DS Dhindsa","year":"2020","unstructured":"Dhindsa DS, Khambhati J, Schultz WM, Tahhan AS, Quyyumi AA. Marital status and outcomes in patients with cardiovascular disease. Trends Cardiovasc Med. 2020;30:215\u201320.","journal-title":"Trends Cardiovasc Med"},{"key":"3255_CR50","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1136\/heartjnl-2018-313005","volume":"104","author":"CW Wong","year":"2018","unstructured":"Wong CW, Kwok CS, Narain A, Gulati M, Mihalidou AS, Wu P, et al. Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis. Heart. 2018;104:1937\u201348.","journal-title":"Heart"},{"issue":"24","key":"3255_CR51","first-page":"00117","volume":"S2090\u20131232","author":"T Guan","year":"2024","unstructured":"Guan T, Monteiro O, Chen D, Luo Z, Chi K, Li Z, et al. Long-term and short-term cardiovascular disease mortality among patients of 21 non-metastatic cancers. J Adv Res. 2024;S2090\u20131232(24):00117\u201326.","journal-title":"J Adv Res"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03255-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:08:23Z","timestamp":1760526503000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03255-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3255"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03255-2","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Its publication is approved by all authors. All authors are in agreement with the content of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"977"}}